Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 18, 2008 - Issue 7
Submit an article Journal homepage
81
Views
6
CrossRef citations to date
0
Altmetric
Reviews

Therapeutic potential of A1 adenosine receptor ligands: a survey of recent patent literature

Irene Giorgi Università di Pisa, Dipartimento di Scienze Farmaceutiche, Via Bonanno 6, 56126 Pisa, Italy +39 50 2219549; +39 50 2219605; [email protected]
&
Paola Nieri Università di Pisa, Dipartimento di Psichiatria, Neurobiologia, Farmacologia e Biotecnologie, Via Bonanno 6, 56126 Pisa, Italy
Pages 677-691 | Published online: 19 Jun 2008

Bibliography

  • Libert K, Van Sande J, Lefort A, et al. Cloning and functional characterization of a human Al adenosine receptor. Biochem Biophys Res Commun 1992;187(2):919-26
  • Fredholm BB, Ijzerman AP, Jacobson KA, et al. International Union of Pharmacology. XXV: Nomenclature and classification of adenosine receptors. Pharmacol Rev 2001;53:527-52
  • Soudijn W, Van Wijngaarden I, Ijzerman AP. Medicinal chemistry of adenosine A1 receptor ligands. Curr Top Med Chem 2003;3:355-67
  • Dhalla AK, Shryock JC, Shreeniwas R, Belardinelli L. Pharmacology and therapeutic applications of A1 adenosine receptor ligands. Curr Top Med Chem 2003;3:369-85
  • Zablocki J, Elzein E, Organ MG, et al. Partial and full agonists of A1 adenosine receptors. WO2006026651; 2006
  • Dhalla AK, Santikul M, Smith M, et al. Antilipolytic activity of a novel partial A1 adenosine receptor agonist devoid of cardiovascular effects: comparison with nicotinic acid. J Pharmacol Exp Ther 2007;32(1):327-33
  • Fatholahi M, Xiang Y, Wu Y, et al. A novel partial agonist of the A1;-adenosine receptor and evidence of receptor homogeneity in adipocytes. J Pharmacol Exp Ther 2006;317(2):676-84
  • ELzein E, Ibrahim P, Palle V, et al. Preparation of nucleosides as partial and full agonists of A1 adenosine receptors. US2005020532; 2005
  • Dhalla A, Elzein E, Ibrahim P, et al. Preparation of nucleosides as partial and full agonists of A1 adenosine receptors. US2007185051; 2007
  • Zablocky J, Palle V, Elzein E, Li X. Partial and full agonists of A1 adenosine receptors. WO2004016635; 2004
  • Zablocky J, Palle V, Elzein E, Li X. Partial and full agonists of A1 adenosine receptors. US20060135467; 2006
  • Elzein E, Kalla R. A1 adenosine receptor agonists. WO2006125211; 2006
  • Elzein E, Kalla R, Li X, et al. N6-cycloalkyl-2-substituted adenosine derivatives as selective, high affinity adenosine A1 receptor agonists. Bioorg Med Chem Lett 2007;17(1):161-6
  • Elzein E, Kalla R, Perry T, et al. A1 adenosine receptor agonists. WO2006125190; 2006
  • Jagtap P, Szabo C, Salzman A. Purine derivatives as adenosine A1 receptor agonists and methods of use thereof. WO2005117910; 2005
  • Jagtap P, Salzman A. purine derivatives and methods of use thereof. WO2007064795; 2007
  • Jagtap P, Salzman A. Purine derivatives and methods of use thereof. WO2007111954; 2007
  • Elzein E, Li X, Zablocky J. A1 adenosine receptor agonists. US2007087994; 2007
  • Gumina G, Beeson C, Wright G. L-nucleosides as ligands to adenosine receptors. US2007054875; 2007
  • Jacobson K, Joshi B, Tchilibon S. Purine derivatives as A3 and A1 adenosine receptor agonists. WO2006031505; 2006
  • Rosentreter U, Kraemer T, Shimada M, et al. Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and the use of the same. WO2003053441; 2003
  • Freiberg C, Knezevic I, Krahn T, et al. Use of adenosine A1 receptor agonists for the protection of renal cells against toxic effects caused by aminoglycosides during treatment of infectious diseases. WO2007073855; 2007
  • Baraldi PG, Fruttarolo F, Tabrizi MA, et al. Novel 8-heterocyclyl xanthine derivatives in drug development: an update. Expert Opin Drug Discov 2007;2(9):1161-83
  • Moro S, Gao ZG, Jacobson KA, Spalluto G. Progress in the pursuit of therapeutic adenosine receptor antagonists. Med Res Rev 2006;26:131-59
  • Yuzlenko O, Kiec-Kononowicz K. Potent adenosine A1 and A2A receptors antagonists: recent developments. Curr Med Chem 2006;13(30):3609-25
  • Jacobson KA, Gao ZG. Adenosine receptors as therapeutic targets. Nat Rev Drug Discov 2006;5(3):247-64
  • Wilson C, Partridge JJ. A1 adenosine receptor antagonists. WO2005009343; 2005
  • Obiefuna PC, Batra VK, Nadeem A, et al. A novel A1 adenosine receptor antagonist (L-97-1) reduces allergic responses to house dust mite in an allergic rabbit model of asthma. J Pharmacol Exp Ther 2005;315:329-36
  • Minaskanian G, Rippel K. Substituted 9-alkyladenines and the use thereof. WO2006099204; 2006
  • Klotz K-N, Kachler S, Lambertucci C, et al. 9-Ethyladenine derivatives as adenosine receptor antagonists: 2- and 8-substitution result in distinct selectivities. Naunyn Schmiedebergs Arch Pharm 2003;367:629-34
  • Cristalli G. A1 adenosine receptor antagonists. US2005245546; 2005
  • Zablocki J, Kalla R. A1 adenosine receptor antagonists. WO2005009445; 2005
  • Akahane A, Kuroda S, Itani H. Pyrazolopyridine as adenosine antagonists. WO0024742; 2000
  • Akahane A. 2-Aminopyrimidine derivatives as adenosine A1 and A2A receptor antagonists. WO2004016605; 2004
  • Yonishi S, Aoki S. Pyrazine derivatives and pharmaceutical use thereof. US2005113387; 2005
  • Yonishi S, Aoki S, et al. Pyrazine derivatives and pharmaceutical use thereof. WO2005040151; 2005
  • Tsutsumi H, Tabuchi S, Minagawa M, Akahane A. Pyrazine derivatives and pharmaceutical use thereof. US2005222159; 2005
  • Castelhano A, Mckibben B, Witter DJ. Compounds specific to adenosine A1 receptors and uses thereof. US2004082599; 2004
  • kalk P, Eggert B, Relle K, et al. The adenosine A1 receptor antagonist SLV320 reduces myocardial fibrosis in rats with 5/6 nephrectomy without affecting blood pressure. Br J Pharmacol 2007;151(7):1025-32
  • Gonzales LL, Camacho GJA. Novel compounds as antagonists for A1 adenosine receptors. WO2007116106; 2007
  • Chang LCW, Ijzerman AP. Pyrimidine derivative as adenosine receptor ligands. WO2005033085; 2005
  • Bruns RF, Fergus JH. Allosteric enhancement of adenosine A1 receptor binding and function by 2-amino-3-benzoylthiophenes. Mol Pharmacol 1990;38:939-49
  • Bruns RF, Fergus JH, Coughenour LL, et al. Structure-activity relationships for enhancement of adenosine A1 receptor binding by 2-amino-3-benzoylthiophenes. Mol Pharmacol 1990;38:950-8
  • Korounakis AP, Van Der Klein PAM, Ijzerman AP. Elucidation of structure-activity relationships of 2-amino-3-benzoylthiophenes: study of their allosteric enhancing vs. antagonistic activity on adenosine A1 receptors. Drug Dev Res 2000;49:227-37
  • Baraldi PG, Zaid AN, Lampronti I, et al. Synthesis and biological effects of a new series of 2-amino-3-benzoylthiophenes as allosteric enhancers of A1-adenosine receptor. Bioorg Med Chem Lett 2000;10:1953-7
  • Tramberg CE, Zickgraf A, Giunta BN, et al. 2-Amino-3-aroyl-4,5-alkylthiophenes: agonist allosteric enhancers at human A1 adenosine receptors. J Med Chem 2002;45:382-9
  • Gao Z-G, Kim S-K, Ijzerman AP, Jacbson KA. Allosteric modulation of the adenosine family of receptors. Mini Rev Med Chem 2005;5:545-53
  • Baraldi PG, Iaconito MA, Moorman AR, et al. Allosteric enhancer for A1 adenosine receptor. Mini Rev Med Chem 2007;7:559-69
  • Baraldi PG. Allosteric adenosine receptor modulators. WO9921617; 1999
  • Baraldi PG. Allosteric adenosine receptor modulators. US2001047008; 2001
  • Linden JM, Olsson RA, Scammells PJ. 2-Amino-3-aroyl-4,5 alkylthiophenes: agonist allosteric enhancers at human A1 adenosine receptors. US2003078248; 2003
  • De Vry J, Kuhl E, Franken-Kunkel P, Eckel G. Pharmacological characterization of the chronic constriction injury model of neuropathic pain. Eur J Pharmacol 2004;491:137-48
  • Lerman BB, Belardinelli L. Cardiac electrophysiology of adenosine. Basic and clinical concepts. Circulation 1991;83(5):1499-509
  • Song Y, Shryock JC, Knot HJ, Belardinelli L. Selective attenuation by adenosine of arrhythmogenic action of isoproterenol on ventricular myocytes. Am J Physiol Heart Circ Physiol 2001;280(6):H2789-95
  • Hebbar AK, Hueston WJ. Management of common arrhythmias: part I. Supraventricular arrhythmias. Am Fam Physician 2002;65(12):2479-86
  • Strickberger SA, Man KC, Daoud EG, et al. Adenosine-induced atrial arrhythmia: a prospective analysis. Ann Intern Med 1997;127(6):417-22. Erratum: Ann Intern Med 1998;128(6):511
  • Lerman BB, Ellenbogen KA, Kadish A, et al. Electrophysiologic effects of a novel selective adenosine A1 agonist (CVT-510) on atrioventricular nodal conduction in humans. J Cardiovasc Pharmacol Ther 2001;6(3):237-45
  • Peterman C, Sanoski CA. Tecadenoson. a novel, selective A1 adenosine receptor agonist. Cardiol Rev 2005;13(6):315-21
  • Ellenbogen KA, O'Neill G, Prystowsky EN, et al. TEMPEST Study Group. Trial to evaluate the management of paroxysmal supraventricular tachycardia during an electrophysiology study with tecadenoson. Circulation 2005;111(24):3202-8
  • Zaza A. CVT-510 (CV Therapeutics). Curr Opin Investig Drugs 2002;3(1):96-100
  • Merkel LA, Rivera LM, Colussi DJ, et al. In vitro and in vivo characterization of an A1-selective adenosine agonist, RG14202. J Pharmacol Exp Ther 1993;265(2):699-706
  • Gadgil S, Wheeler W. Method of treating atrial fibrillation or atrial flutter. US2005009776; 2005
  • Aurora J, Gill MS, Ong KKH. Controlled release formulation. WO2005025545; 2005
  • NCT00040001. Safety and efficacy study of an A1-adenosine receptor agonist to slow heart rate in atrial fibrillation . Available from: http://clinicaltrials.gov/ct2/show/NCT00040001
  • NCT00568945. Study to investigate the effect of the A1 agonist capadenoson on ventricular hr in patients with persistent or permanent atrial fibrillation . Available from: http://clinicaltrials.gov/ct2/show/NCT00568945
  • Song Y, Wu L, Shryock JC, Belardinelli L. Selective attenuation of isoproterenol-stimulated arrhythmic activity by a partial agonist of adenosine A1 receptor. Circulation 2002;105(1):118-23
  • Donato M, Gelpi RJ. Adenosine and cardioprotection during reperfusion: an overview. Mol Cell Biochem 2003;251:153-9
  • Headrick JP, Gauthier NS, Morrison RR, Matherne GP. Cardioprotection by K(ATP) channels in wild-type hearts and hearts overexpressing A1;-adenosine receptors. Am J Physiol Heart Circ Physiol 2000;279(4):H1690-7
  • Yang Z, Cerniway RJ, Byford AM, et al. Cardiac overexpression of A1-adenosine receptor protects intact mice against myocardial infarction. Am J Physiol Heart Circ Physiol 2002;282(3):H949-55
  • Lankford AR, yang JN, Rose'meyer R, et al. Effect of modulating cardiac A1 adenosine receptor expression on protection with ischemic preconditioning. Am J Physiol Heart Circ Physiol 2006;290(4):H1469-73
  • Yang Z, Day YJ, Toufektsian MC, et al. Myocardial infarct-sparing effect of adenosine A2A receptor activation is due to its action on CD4+ T lymphocytes. Circulation 2006;114(19):2056-64
  • De Jonge R, Out M, Maas WJ, De Jong JW. Preconditioning of rat hearts by adenosine A1 or A3 receptor activation. Eur J Pharmacol 2002;441(3):165-72
  • Eckle T, Krahn T, Grenz A, et al. Cardioprotection by ecto-5′-nucleotidase (CD73) and A2B adenosine receptors. Circulation 2007;115(12):1581-90
  • Sawynok J, Liu XJ. Adenosine in the spinal cord and periphery: release and regulation of pain. Prog Neurobiol 2003;69(5):313-40
  • Liu XJ, Salter MW. Purines and pain mechanisms: recent developments. Curr Opin Investig Drugs 2005;6(1):65-75
  • Zahn PK, Straub H, Wenk M, Pogatzki-Zahn EM. Adenosine A1 but not A2a receptor agonist reduces hyperalgesia caused by a surgical incision in rats: a pertussis toxin-sensitive G protein-dependent process. Anesthesiology 2007;107(5):797-806
  • Lim WK. GPCR drug discovery: novel ligands for CNS receptors. Recent Patents CNS Drug Discov 2007;2(2):107-12
  • Giffin NJ, Kowacs F, Libri V, et al. Effect of the adenosine A1 receptor agonist GR79236 on trigeminal nociception with blink reflex recordings in healthy human subjects. Cephalalgia 2003;23(4):287-92
  • NCT00376454. The study of GW493838, an adenosine A1 agonist, in peripheral neuropathic pain. Available from: http://clinicaltrials.gov/ct2/show/NCT00376454
  • NCT00506610. A study to determine if an investigational pain medicine provides relief of chronic pain after a shingles outbreak. Available from: http://clinicaltrials.gov/ct2/show/NCT00506610
  • NCT00298636. Dose-response of adenosine for perioperative pain. Available from: http://clinicaltrials.gov/ct2/show/NCT00298636
  • NCT00349921. Clonidine versus adenosine to treat neuropathic pain. Available from: http://clinicaltrials.gov/ct2/show/NCT00349921
  • Stone TW. Adenosine, neurodegeneration and neuroprotection. Neurol Res 2005;27(2):161-8
  • Ribeiro JA. What can adenosine neuromodulation do for neuroprotection? Curr Drug Targets CNS Neurol Disord 2005;4(4):325-9
  • Benarroch EE. Adenosine and its receptors: multiple modulatory functions and potential therapeutic targets for neurologic disease. Neurology 2008;70(3):231-6
  • Von Lubitz DK, Lin RC, Paul IA, et al. Postischemic administration of adenosine amine congener (ADAC): analysis of recovery in gerbils. Eur J Pharmacol 1996;316(2-3):171-9
  • Knutsen LJ, Lau J, Petersen H, et al. N-substituted adenosines as novel neuroprotective A1; agonists with diminished hypotensive effects. J Med Chem 1999;42(18):3463-77
  • Jacobson KA, Von Lubitz DK, Daly JW, Fredholm BB. Adenosine receptor ligands: differences with acute versus chronic treatment. Trends Pharmacol Sci 1996;17(3):108-13
  • Coelho JE, Rebola N, Fragata I, et al. Hypoxia-induced desensitization and internalization of adenosine A1 receptors in the rat hippocampus. Neuroscience 2006;138(4):1195-203
  • NCT00182312. Caffeine for apnea of prematurity (CAP). Available from: http://clinicaltrials.gov/ct2/show/NCT00182312
  • Schmidt B, Roberts RS, Davis P, et al. Long-term effects of caffeine therapy for apnea of prematurity. N Engl J Med 2007;357(19):1893-902
  • Rezvani ME, Mirnajafi-Zadeh J, Fathollahi Y, Palizvan MR. Anticonvulsant effect of A1 but not A2A adenosine receptors of piriform cortex in amygdala-kindled rats. Can J Physiol Pharmacol 2007;85(6):606-12
  • Schindler CW, Karcz-Kubicha M, Thorndike EB, et al. Role of central and peripheral adenosine receptors in the cardiovascular responses to intraperitoneal injections of adenosine A1 and A2A subtype receptor agonists. Br J Pharmacol 2005;144(5):642-50
  • Lee HT, Emala CW. Protective effects of renal ischemic preconditioning and adenosine pretreatment: role of A1; and A3; receptors. Am J Physiol Renal Physiol 2000;278(3):F380-7
  • Lee HT, Xu H, Nasr SH, et al. A1 adenosine receptor knockout mice exhibit increased renal injury following ischemia and reperfusion. Am J Physiol Renal Physiol 2004;286(2):F298-306
  • Vallon V, Mühlbauer B, Osswald H. Adenosine and kidney function. Physiol Rev 2006;86(3):901-40
  • Joo JD, Kim M, Horst P, et al. Acute and delayed renal protection against renal ischemia and reperfusion injury with A1 adenosine receptors. Am J Physiol Renal Physiol 2007;293(6):F1847-57
  • Vannucci SJ, Klim CM, Martin LF, Lanoue KF. A1-adenosine receptor-mediated inhibition of adipocyte adenylate cyclase and lipolysis in Zucker rats. Am J Physiol Endocrinol Metab 1989;257:E871-8
  • Dong Q, Ginsberg HN, Erlanger BF. Overexpression of the A1 adenosine receptor in adipose tissue protects mice from obesity-related insulin resistance. Diabetes Obes Metab 2001;3(5):360-6
  • Boden G. Pathogenesis of type 2 diabetes. Insulin resistance. Endocrinol Metab Clin North Am 2001;30(4):801-15
  • Qu X, Cooney G, Donnelly R. Short-term metabolic and haemodynamic effects of GR79236 in normal and fructose-fed rats. Eur J Pharmacol 1997;338(3):269-76
  • Dhalla AK, Wong MY, Voshol PJ, et al. A1 adenosine receptor partial agonist lowers plasma FFA and improves insulin resistance induced by high-fat diet in rodents. Am J Physiol Endocrinol Metab 2007;292(5):E1358-63
  • Wilson CN, Borron P. Methods and compositions for producing antigenic responses. US20050075308; 2005
  • Wilson CN, Batra VK. Lipopolysaccharide binds to and activates A1 adenosine receptors on human pulmonary artery endothelial cells. J Endotoxin Res 2002;8:263-71
  • Mayne M, Shepel PN, Jiang Y, et al. Dysregulation of adenosine A1 receptor-mediated cytokine expression in peripheral blood mononuclear cells from multiple sclerosis patients. Ann Neurol 1999;45:633-9
  • Johnston JB, Silva C, Gonzalez G, et al. Diminished adenosine A1 receptor expression on macrophages in brain and blood of patients with multiple sclerosis. Ann Neurol 2001;49(5):650-8
  • Welch WJ. Adenosine type 1 receptor antagonists in fluid retaining disorders. Expert Opin Investig Drugs 2002;11(11):1553-62
  • Greenberg B, Thomas I, Banish D, et al. Effects of multiple oral doses of an A1 adenosine antagonist, BG9928, in patients with heart failure: results of a placebo-controlled, dose-escalation study. J Am Coll Cardiol 2007;50(7):600-6
  • NCT00354458. A study of the selective A1 adenosine receptor antagonist KW-3902 for patients hospitalized with acute HF and volume overload to assess treatment effect on congestion and renal function. Available from: http://clinicaltrials.gov/ct2/show/NCT00354458
  • NCT00328692. A study of the selective A1 adenosine receptor antagonist KW-3902 for patients hospitalized with acute HF and volume overload to assess treatment effect on congestion and renal function. Available from: http://clinicaltrials.gov/ct2/show/NCT00328692
  • NCT00443690. Placebo-controlled randomized study of KW-3902 for subjects hospitalized with worsening renal function and heart failure requiring IV therapy (REACH UP). Available from: http://clinicaltrials.gov/ct2/show/NCT00443690
  • Dittrich H, Farmer B. Method of improved diuresis in individuals with impaired renal function. WO2007149285; 2007
  • Miracle CM, Rieg T, Blantz RC, et al. Combined effects of carbonic anhydrase inhibitor and adenosine A1 receptor antagonist on hemodynamic and tubular function in the kidney. Kidney Blood Press Res 2007;30(6):388-99
  • Dittrich HC, Gupta DK, Hack TC, et al. The effect of KW-3902, an adenosine A1 receptor antagonist, on renal function and renal plasma flow in ambulatory patients with heart failure and renal impairment. J Card Fail 2007;13(8):609-17
  • Givertz MM, Massie BM, Fields TK, et al. CKI-201 and CKI-202 Investigators. The effects of KW-3902, an adenosine A1-receptor antagonist, on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance. J Am Coll Cardiol 2007;50(16):1551-60
  • Cleland JG, Coletta AP, Abdellah AT, et al. Clinical trials update from Heart Rhythm and Heart Failure 2007: CARISMA, PREPARE, DAVID II, SAVE-PACE, PROTECT and AREA-IN-CHF. Eur J Heart Fail 2007;9(8):850-3
  • kalk P, Eggert B, Relle K, et al. The adenosine A1 receptor antagonist SLV320 reduces myocardial fibrosis in rats with 5/6 nephrectomy without affecting blood pressure. Br J Pharmacol 2007;151(7):1025-32
  • NCT00160134. Study to evaluate cardiac hemodynamics and safety of SLV320 in subjects with congestive heart failure. Available from: http://clinicaltrials.gov/ct2/show/NCT00160134
  • NCT00568009. Study to evaluate the effect of SLV320 in addition to chronic furosemide treatment on renal function in subjects with congestive heart failure and impaired renal function. Available from: http://clinicaltrials.gov/ct2/show/NCT00568009
  • Otsuki L, Widder K. Combination therapy comprising an adenosine A1 receptor antagonist and an aldosterone inhibitor. WO2005105083; 2005
  • Dittrich H, Farmer B. Prolonged improvement of renal function comprising infrequent administration of an AA1RA. WO2007149366; 2007
  • Erley CM, Heyne N, Burgert K, et al. Prevention of radiocontrast-induced nephropathy by adenosine antagonists in rats with chronic nitric oxide deficiency. J Am Soc Nephrol 1997;8:1125-32
  • Yao K, Heyne N, Erley CM, et al. The selective adenosine A1 receptor antagonist KW-3902 prevents radiocontrast media-induced nephropathy in rats with chronic nitric oxide deficiency. Eur J Pharmacol 2001;414:99-10
  • Hocher B, Fischer Y. Use of adenosine A1 antagonists in radiocontrast media induced nephropathy. US2008027082; 2008
  • Spicuzza L, Di Maria G, Polosa R. Adenosine in the airways: implications and applications. Eur J Pharmacol 2006;533(1-3):77-88
  • Nyce JW, Metzger WJ. DNA antisense therapy for asthma in an animal model. Nature 1997;385(6618):721-5
  • Obiefuna PC, Batra VK, Nadeem A, et al. A novel A1 adenosine receptor antagonist, L-97-1, 3-2-(4-aminophenyl)-ethyl-8-benzyl-7-{2-ethyl-(2-hydroxy-ethyl)-amino-ethyl}-1-propyl-3,7-dihydro-purine-2,6-dione, reduces allergic responses to house dust mite in an allergic rabbit model of asthma. J Pharmacol Exp Ther 2005;315(1):329-36
  • Nadeem A, Obiefuna PC, Wilson CN, Mustafa SJ. Adenosine A1 receptor antagonist versus montelukast on airway reactivity and inflammation. Eur J Pharmacol 2006;551(1-3):116-24
  • Wilson CN, Partridge J. Compositions and methods for treating respiratory disorders. WO2007103970; 2007
  • Evans BAJ, Ham J. The role of adenosine in bone: an emerging concept. Immunol Endocrine Metab Agents Med Chem 2007;7(4):322-7
  • Cronstein B, Kara Firas M. Methods and compositions for treating disorders associated with increased bone turnover and osteopenia. WO2007095161; 2007
  • Neely CF, Jin J, Keith IM. A1-adenosine receptor antagonists block endotoxin-induced lung injury. Am J Physiol 1997;272:L353-61
  • Wilson CN, Batra V. Lipopolysaccharide binds to and activates A1 adenosine receptors on human pulmonary artery endothelial cells. J Endotoxin Res 2002;8:263-71
  • Wilson CN. Methods and pharmaceutical compositions for treating sepsis. US2006276378; 2006
  • Back SA, Craig A, Luo NL, et al. Protective effects of caffeine on chronic hypoxia-induced perinatal white matter injury. Ann Neurol 2006;60(6):696-705
  • Magata S, Taniguchi M, Suzuki T, et al. The effect of antagonism of adenosine A1 receptor against ischemia and reperfusion injury of the liver. J Surg Res 2007;139(1):7-14
  • Lee HT, Emala CW. Protective effects of renal ischemic preconditioning and adenosine pretreatment: role of A1; and A3; receptors. Am J Physiol Renal Physiol 2000;278(3):F380-7
  • Brown RA, Spina D, Page CP. Adenosine receptors and asthma. Br J Pharmacol 2008;153(Suppl 1):S446-56
  • Maemoto T, Tada M, Mihara T, et al. Pharmacological characterization of FR194921, a new potent, selective, and orally active antagonist for central adenosine A1 receptors. J Pharmacol Sci 2004;96(1):42-52
  • Available from: www.clinicaltrials.gov

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.